Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Income Statement
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The analysis of investment activity ratios reveals a period of stability in asset utilization contrasted by an exponential increase in equity turnover. While the efficiency of fixed and total assets remained relatively consistent over the observed timeframe, the relationship between equity and revenue underwent a significant transformation.
- Net Fixed Asset Turnover
- The ratio maintained a narrow range between 10.80 and 11.82. A peak was observed in September 2022 at 11.82, followed by a gradual moderation. From March 2024 through March 2026, the ratio stabilized between 10.80 and 11.05, indicating a consistent level of efficiency in leveraging fixed assets to generate revenue.
- Total Asset Turnover
- Total asset utilization remained stable for the majority of the period, fluctuating primarily between 0.37 and 0.42 from March 2022 to December 2023. A slight dip to 0.37 occurred in March 2024, which was followed by a steady upward trend, reaching a peak of 0.46 by March 2026. This suggests a marginal improvement in the overall efficiency of the company's total asset base in driving sales.
- Equity Turnover
- A dramatic escalation in equity turnover is observed, starting from 3.48 in March 2022 and rising to 40.40 by March 2025. The growth accelerated sharply beginning in March 2024, moving from 6.79 to 16.94 by December 2024, and finally to 40.40. Such a substantial increase indicates a significant reduction in the equity base relative to revenue, which typically suggests aggressive capital restructuring, substantial share repurchases, or large dividend distributions.
Net Fixed Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net revenues | |||||||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net fixed asset turnover
= (Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of the net fixed asset turnover ratio indicates a period of initial growth followed by a gradual decline and subsequent stabilization. The ratio reached a peak of 11.82 by the third quarter of 2022 before entering a downward trajectory that lasted through the end of 2023, eventually settling into a narrow range between 10.80 and 11.05 through the first quarter of 2026.
- Revenue Generation Efficiency
- Net revenues exhibited quarterly fluctuations but maintained a general long-term upward trend, rising from 13,538 million USD in March 2022 to 15,002 million USD in March 2026. The efficiency of asset utilization peaked in 2022, coinciding with a period where revenue growth outpaced the growth of the fixed asset base.
- Fixed Asset Base Dynamics
- Property and equipment, net, remained relatively stable during the first half of the analyzed period, dipping slightly before stabilizing around 4,900 million USD. A gradual increase in investment is observed starting in 2024, with net fixed assets climbing to 5,687 million USD by March 2026. This expansion of the asset base contributed to the moderate compression of the turnover ratio during the latter half of the period.
- Ratio Stability and Correlation
- The stabilization of the net fixed asset turnover ratio around the 10.9 to 11.0 level suggests a proportional relationship between capital expenditure and revenue growth. While revenues continued to increase, the concurrent expansion of the fixed asset base prevented the turnover ratio from increasing further, indicating that investments in property and equipment are scaling in alignment with revenue trajectory.
Total Asset Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net revenues | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Total asset turnover
= (Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of asset utilization reveals a general improvement in efficiency over the observed period, characterized by an initial phase of stability and a subsequent upward trend in the total asset turnover ratio.
- Revenue and Asset Dynamics
- Net revenues exhibit a consistent long-term growth pattern, rising from 13,538 million USD in March 2022 to a peak of 16,618 million USD in December 2025. During this same period, total assets remained relatively range-bound, fluctuating between approximately 133 billion USD and 149 billion USD. This divergence—growing revenues against a relatively stable asset base—contributed to the expansion of the turnover ratio in the latter half of the analysis period.
- Total Asset Turnover Trend Analysis
- The total asset turnover ratio remained stable between 0.40 and 0.42 throughout 2022 and 2023. A notable contraction occurred in March 2024, where the ratio reached a period low of 0.37. This decline coincided with a sharp increase in total assets to 148,874 million USD, representing a temporary decrease in asset efficiency. However, from December 2024 through March 2026, the ratio demonstrated a sustained recovery, climbing steadily to reach a peak of 0.46.
- Operational Efficiency Insights
- The rise in the ratio to 0.46 by the end of the period indicates a more effective deployment of the asset base to generate top-line growth. The stability of the asset base during 2025, paired with record quarterly revenues, suggests an optimization of operational capacity and an improved ability to generate sales from the company's invested assets.
Equity Turnover
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net revenues | |||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Equity turnover
= (Net revenuesQ1 2026
+ Net revenuesQ4 2025
+ Net revenuesQ3 2025
+ Net revenuesQ2 2025)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
An analysis of the financial activity from March 2022 through March 2026 reveals a divergent trend between revenue generation and the capital base. While net revenues maintained a general upward trajectory, there was a severe and consistent contraction in stockholders' equity, eventually resulting in a significant equity deficit.
- Net Revenue Trends
- Net revenues exhibited steady growth over the observed period, rising from 13,538 million USD in March 2022 to a peak of 16,618 million USD in December 2025. This represents a consistent ability to generate sales, with quarterly fluctuations remaining within a manageable range.
- Stockholders' Equity Contraction
- A systemic decline in stockholders' equity is observed, falling from 16,283 million USD in March 2022 to 3,325 million USD by December 2024. The equity base entered negative territory in June 2025 (-183 million USD) and continued to deteriorate, reaching a deficit of 6,656 million USD by March 2026.
- Equity Turnover Dynamics
- The equity turnover ratio experienced an exponential increase, moving from 3.48 in March 2022 to 40.40 by March 2025. This surge is not attributable to an acceleration in revenue growth, which remained linear, but is instead a mathematical consequence of the rapidly diminishing equity base. The ratio's escalation reflects an increasing reliance on debt or other liabilities to fund operations as the equity cushion vanished.
The combination of growing revenues and a collapsing equity base indicates a significant shift in the capital structure. The transition to negative equity by mid-2025 renders the equity turnover ratio an unreliable indicator of operational efficiency, as the ratio's spike is driven by the proximity of the equity value to zero.